6JH Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IN8bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.78 |
| 52 Week High | US$6.13 |
| 52 Week Low | US$1.96 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -7.33% |
| 1 Year Change | -50.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -66.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6JH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | -1.0% |
| 1Y | -50.2% | -9.9% | 12.8% |
Return vs Industry: 6JH underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: 6JH underperformed the German Market which returned 6.3% over the past year.
Price Volatility
| 6JH volatility | |
|---|---|
| 6JH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6JH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6JH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 26 | Will Ho | in8bio.com |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers.
IN8bio, Inc. Fundamentals Summary
| 6JH fundamental statistics | |
|---|---|
| Market cap | €35.54m |
| Earnings (TTM) | -€25.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs 6JH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6JH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.57m |
| Earnings | -US$26.57m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6JH perform over the long term?
See historical performance and comparison